List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6224911/publications.pdf Version: 2024-02-01

		23500	37111
310	12,883	58	96
papers	citations	h-index	g-index
215	215	215	10007
515	515	515	15557
all docs	docs citations	times ranked	citing authors

IAN EDAZED

#	Article	IF	CITATIONS
1	Changes in the skin microbiome associated with squamous cell carcinoma in transplant recipients. ISME Communications, 2022, 2, .	1.7	6
2	Analysis of human leukocyte antigen associations in human papillomavirus–positive and –negative head and neck cancer: Comparison with cervical cancer. Cancer, 2022, 128, 1937-1947.	2.0	6
3	Skin Cancer-Associated S. aureus Strains Can Induce DNA Damage in Human Keratinocytes by Downregulating DNA Repair and Promoting Oxidative Stress. Cancers, 2022, 14, 2143.	1.7	8
4	Cancer vaccines. Cancer Cell, 2022, 40, 559-564.	7.7	15
5	Regulatory T Cells but Not IL-10 Impair Cell-Mediated Immunity in Human Papillomavirus E7+ Hyperplastic Epithelium. Journal of Investigative Dermatology, 2021, 141, 1264-1273.e3.	0.3	3
6	A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC). Cancer Immunology, Immunotherapy, 2021, 70, 743-753.	2.0	18
7	Manganese-Doped Silica-Based Nanoparticles Promote the Efficacy of Antigen-Specific Immunotherapy. Journal of Immunology, 2021, 206, 987-998.	0.4	16
8	Antigen Nonspecific Induction of Distinct Regulatory T Cell States in Oncogene-Driven Hyperproliferative Skin. ImmunoHorizons, 2021, 5, 102-116.	0.8	3
9	Immune-Inhibitory Gene Expression is Positively Correlated with Overall Immune Activity and Predicts Increased Survival Probability of Cervical and Head and Neck Cancer Patients. Frontiers in Molecular Biosciences, 2021, 8, 622643.	1.6	13
10	Editorial: Immunology of HPV Infection and Vaccination: Progress and Challenges. Frontiers in Immunology, 2021, 12, 665463.	2.2	0
11	IFN-Î ³ Critically Enables the Intratumoural Infiltration of CXCR3+ CD8+ T Cells to Drive Squamous Cell Carcinoma Regression. Cancers, 2021, 13, 2131.	1.7	7
12	Scavenging of soluble and immobilized CCL21 by ACKR4 regulates peripheral dendritic cell emigration. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	22
13	Absence of Batf3 reveals a new dimension of cell state heterogeneity within conventional dendritic cells. IScience, 2021, 24, 102402.	1.9	16
14	Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions. Vaccines, 2021, 9, 535.	2.1	38
15	Salivary High-Risk Human Papillomavirus (HPV) DNA as a Biomarker for HPV-Driven Head and Neck Cancers. Journal of Molecular Diagnostics, 2021, 23, 1334-1342.	1.2	26
16	Determining the utility of a screening program to reduce the incidence of HPV driven oropharyngeal cancer. Oncoscience, 2021, 8, 91-93.	0.9	3
17	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. Science Translational Medicine, 2021, 13, eabd5524.	5.8	62
18	Acquisition of murine splenic myeloid cells for protein and gene expression profiling by advanced flow cytometry and CITE-seq. STAR Protocols, 2021, 2, 100842.	0.5	2

#	Article	IF	CITATIONS
19	Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TCâ€1 tumorâ€bearing mice with PDâ€1 blockade by modulating macrophage heterogeneity and the activation of CD8 ⁺ T cells in the tumor microenvironment. Clinical and Translational Immunology, 2021, 10, e1335.	1.7	12
20	A model of impaired Langerhans cell maturation associated with HPV induced epithelial hyperplasia. IScience, 2021, 24, 103326.	1.9	7
21	An update on cervical cancer screening in Vanuatu. International Journal of Gynecological Cancer, 2021, 31, 631-632.	1.2	0
22	Secreted Toxins From Staphylococcus aureus Strains Isolated From Keratinocyte Skin Cancers Mediate Pro-tumorigenic Inflammatory Responses in the Skin. Frontiers in Microbiology, 2021, 12, 789042.	1.5	14
23	Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method. Frontiers in Immunology, 2020, 11, 585768.	2.2	3
24	Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma. Cancer Science, 2020, 111, 3854-3861.	1.7	31
25	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 2020, 180, 895-914.e27.	13.5	127
26	Dysregulation of Stemness Pathways in HPV Mediated Cervical Malignant Transformation Identifies Potential Oncotherapy Targets. Frontiers in Cellular and Infection Microbiology, 2020, 10, 307.	1.8	15
27	Oral HPV16 Prevalence in Oral Potentially Malignant Disorders and Oral Cavity Cancers. Biomolecules, 2020, 10, 223.	1.8	22
28	Antibody-Free Multiplex Measurement of 23 Human Cytokines in Primary Cell Culture Secretome Using Targeted Mass Spectrometry. Analytical Chemistry, 2020, 92, 3742-3750.	3.2	7
29	Importance of human papillomavirus infection in squamous cell carcinomas of the tongue in Guangdong Province, China. Journal of International Medical Research, 2020, 48, 030006051989718.	0.4	2
30	Collaboration in the War against Viruses: A Multidisciplinary International Effort. Innovation(China), 2020, 1, 100011.	5.2	6
31	The Innovation: A Journal to See the Unseen and Change the Unchanged. Innovation(China), 2020, 1, 100014.	5.2	1
32	Single-cell RNA sequencing reveals cell type-specific HPV expression in hyperplastic skin lesions. Virology, 2019, 537, 14-19.	1.1	19
33	Immunotherapy for HPV associated cancer. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100176.	4.5	26
34	Acute exercise does not improve immune response to HPV vaccination series in adolescents. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100178.	4.5	2
35	HPV16 E7-Driven Epithelial Hyperplasia Promotes Impaired Antigen Presentation and Regulatory T-Cell Development. Journal of Investigative Dermatology, 2019, 139, 2467-2476.e3.	0.3	9
36	Microprojection arrays applied to skin generate mechanical stress, induce an inflammatory transcriptome and cell death, and improve vaccine-induced immune responses. Npj Vaccines, 2019, 4, 41.	2.9	23

#	Article	IF	CITATIONS
37	Human papillomavirus infection among head and neck squamous cell carcinomas in southern China. PLoS ONE, 2019, 14, e0221045.	1.1	30
38	The HPV Vaccine Story. ACS Pharmacology and Translational Science, 2019, 2, 210-212.	2.5	9
39	Unlocking the Potential of Saliva-Based Test to Detect HPV-16-Driven Oropharyngeal Cancer. Cancers, 2019, 11, 473.	1.7	32
40	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. Gynecologic Oncology, 2019, 152, 465-471.	0.6	14
41	Cytokine/chemokine profiles in squamous cell carcinoma correlate with precancerous and cancerous disease stage. Scientific Reports, 2019, 9, 17754.	1.6	11
42	Selective Persistence of HPV Cross-Neutralising Antibodies following Reduced-Dose HPV Vaccine Schedules. Vaccines, 2019, 7, 200.	2.1	8
43	Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. PLoS ONE, 2019, 14, e0226320.	1.1	20
44	Highâ€risk human papillomavirus detection in oropharyngeal cancers: Comparison of saliva sampling methods. Head and Neck, 2019, 41, 1484-1489.	0.9	18
45	An ExÂVivo Human Tumor Assay Shows DistinctÂPatterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes. Journal of Investigative Dermatology, 2019, 139, 213-223.	0.3	19
46	The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health, The, 2019, 4, e19-e27.	4.7	268
47	No Vacillation on HPV Vaccination. Cell, 2018, 172, 1163-1167.	13.5	20
48	HPV16E7-Induced Hyperplasia Promotes CXCL9/10 Expression and Induces CXCR3+ T-Cell Migration to Skin. Journal of Investigative Dermatology, 2018, 138, 1348-1359.	0.3	21
49	Murine HPV16 E7-expressing transgenic skin effectively emulates the cellular and molecular features of human high-grade squamous intraepithelial lesions. Papillomavirus Research (Amsterdam,) Tj ETQq1 1 0.7843	144.gBT /C	Overbock 10
50	Eradicating HPV-Associated Cancer Through Immunization: A Glass Half Full…. Viral Immunology, 2018, 31, 80-85.	0.6	3
51	<scp>CD</scp> 8 ⁺ lineage dendritic cells determine adaptive immune responses to inflammasome activation upon sterile skin injury. Experimental Dermatology, 2018, 27, 71-79.	1.4	10
52	Recruitment of Antigen Presenting Cells to Skin Draining Lymph Node From HPV16E7-Expressing Skin Requires E7-Rb Interaction. Frontiers in Immunology, 2018, 9, 2896.	2.2	6
53	A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes. MBio, 2018, 9, .	1.8	37
54	Examining the contribution of smoking and HPV towards the etiology of oral cavity squamous cell carcinoma using high-throughput sequencing: A prospective observational study. PLoS ONE, 2018, 13, e0205406.	1.1	13

#	Article	IF	CITATIONS
55	Detection of HPV E7 Transcription atÂSingle-Cell Resolution in Epidermis. Journal of Investigative Dermatology, 2018, 138, 2558-2567.	0.3	19
56	Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatchâ,,¢). Vaccine, 2018, 36, 3779-3788.	1.7	93
57	Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8 ⁺ Effector Memory T Cell Function In The Skin and Allow their Infiltration into Cutaneous Squamous Cell Carcinoma. Oncolmmunology, 2018, 7, e1479627.	2.1	16
58	HLAandKIRAssociations of Cervical Neoplasia. Journal of Infectious Diseases, 2018, 218, 2006-2015.	1.9	22
59	Human papillomavirus E7 oncoprotein expression by keratinocytes alters the cytotoxic mechanisms used by CD8 T cells. Oncotarget, 2018, 9, 6015-6027.	0.8	6
60	Batf3 selectively determines acquisition of CD8 ⁺ dendritic cell phenotype and function. Immunology and Cell Biology, 2017, 95, 215-223.	1.0	22
61	CD4+CD8β+ double-positive T cells in skin-draining lymph nodes respond to inflammatory signals from the skin. Journal of Leukocyte Biology, 2017, 102, 837-844.	1.5	5
62	Clinical development strategy for a candidate group A streptococcal vaccine. Vaccine, 2017, 35, 2007-2014.	1.7	18
63	Modulation of antigen presenting cell functions during chronic HPV infection. Papillomavirus Research (Amsterdam, Netherlands), 2017, 4, 58-65.	4.5	48
64	DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection. Journal of Immunotherapy, 2017, 40, 62-70.	1.2	39
65	HPV16-E7-Specific Activated CD8 T Cells in E7 Transgenic Skin and Skin Grafts. Frontiers in Immunology, 2017, 8, 524.	2.2	8
66	A Pilot Study into the Association between Oral Health Status and Human Papillomavirus—16 Infection. Diagnostics, 2017, 7, 11.	1.3	47
67	Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death and Disease, 2017, 8, e2836-e2836.	2.7	327
68	Defining the genetic susceptibility to cervical neoplasia—A genome-wide association study. PLoS Genetics, 2017, 13, e1006866.	1.5	105
69	The overexpression of salivary cytokeratins as potential diagnostic biomarkers in head and neck squamous cell carcinomas. Oncotarget, 2017, 8, 72272-72280.	0.8	20
70	RNA-seq reveals more consistent reference genes for gene expression studies in human non-melanoma skin cancers. PeerJ, 2017, 5, e3631.	0.9	39
71	Epithelium Expressing the E7 Oncoprotein of HPV16 Attracts Immune-Modulatory Dendritic Cells to the Skin and Suppresses Their Antigen-Processing Capacity. PLoS ONE, 2016, 11, e0152886.	1.1	24
72	Role of Ultraviolet Radiation in Papillomavirus-Induced Disease. PLoS Pathogens, 2016, 12, e1005664.	2.1	68

#	Article	IF	CITATIONS
73	Sustained antibody responses six years following one, two, or three doses of quadrivalent HPV vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study. Clinical Infectious Diseases, 2016, 64, ciw865.	2.9	25
74	Immunotherapy for cancer: progress at a cost we can afford?. Pathology, 2016, 48, S3.	0.3	0
75	An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1. Human Vaccines and Immunotherapeutics, 2016, 12, 3079-3088.	1.4	27
76	A Mouse Model of Hyperproliferative Human Epithelium Validated by Keratin Profiling Shows an Aberrant Cytoskeletal Response to Injury. EBioMedicine, 2016, 9, 314-323.	2.7	27
77	A pilot study to compare the detection of HPV-16 biomarkers in salivary oral rinses with tumour p16INK4a expression in head and neck squamous cell carcinoma patients. BMC Cancer, 2016, 16, 178.	1.1	65
78	Does the nature of residual immune function explain the differential risk of nonâ€melanoma skin cancer development in immunosuppressed organ transplant recipients?. International Journal of Cancer, 2016, 138, 281-292.	2.3	38
79	The Actinic Keratosis Virome: Can We Prevent Squamous Cell Carcinoma with a Vaccine?. Current Problems in Dermatology, 2015, 46, 28-35.	0.8	5
80	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. Oncolmmunology, 2015, 4, e998538.	2.1	119
81	Interleukin-17A Promotes Arginase-1 Production and 2,4-Dinitrochlorobenzene-Induced Acute Hyperinflammation in Human Papillomavirus E7 Oncoprotein-Expressing Skin. Journal of Innate Immunity, 2015, 7, 392-404.	1.8	14
82	HPV16 E7 expression in skin induces TSLP secretion, type 2 ILC infiltration and atopic dermatitisâ€like lesions. Immunology and Cell Biology, 2015, 93, 540-547.	1.0	10
83	Langerhans Cell Homeostasis and Activation Is Altered in Hyperplastic Human Papillomavirus Type 16 E7 Expressing Epidermis. PLoS ONE, 2015, 10, e0127155.	1.1	20
84	The Kinematics of Cytotoxic Lymphocytes Influence Their Ability to Kill Target Cells. PLoS ONE, 2014, 9, e95248.	1.1	19
85	Comparative Immune Phenotypic Analysis of Cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in Immune-Competent Individuals: Proportional Representation of CD8+ T-Cells but Not FoxP3+ Regulatory T-Cells Is Associated with Disease Stage. PLoS ONE, 2014, 9, e110928.	1.1	35
86	Human Papillomavirus E7 Oncoprotein Transgenic Skin Develops an Enhanced Inflammatory Response to 2,4-Dinitrochlorobenzene by an Arginase-1-Dependent Mechanism. Journal of Investigative Dermatology, 2014, 134, 2438-2446.	0.3	11
87	IL-18, but Not IL-12, Induces Production of IFN-γ in the Immunosuppressive Environment of HPV16 E7 Transgenic Hyperplastic Skin. Journal of Investigative Dermatology, 2014, 134, 2562-2569.	0.3	38
88	HPV16-E7 Expression in Squamous Epithelium Creates a Local Immune Suppressive Environment via CCL2- and CCL5- Mediated Recruitment of Mast Cells. PLoS Pathogens, 2014, 10, e1004466.	2.1	55
89	The early monocytic response to cytomegalovirus infection isMyD88 dependent but occurs independently of common inflammatory cytokine signals. European Journal of Immunology, 2014, 44, 409-419.	1.6	7
90	Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30Âyears with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study. BMC Infectious Diseases, 2014, 14, 3861.	1.3	8

#	Article	IF	CITATIONS
91	Colocalization of Cell Death with Antigen Deposition in Skin Enhances Vaccine Immunogenicity. Journal of Investigative Dermatology, 2014, 134, 2361-2370.	0.3	83
92	Microprojection arrays to immunise at mucosal surfaces. Journal of Controlled Release, 2014, 196, 252-260.	4.8	31
93	IL-17 Suppresses Immune Effector Functions in Human Papillomavirus-Associated Epithelial Hyperplasia. Journal of Immunology, 2014, 193, 2248-2257.	0.4	57
94	CXCL1 gene silencing in skin using liposome-encapsulated siRNA delivered by microprojection array. Journal of Controlled Release, 2014, 194, 148-156.	4.8	31
95	Recombinant <scp>W</scp> nt3a and <scp>W</scp> nt5a elicit macrophage cytokine production and tolerization to microbial stimulation via <scp>T</scp> ollâ€kike receptor 4. European Journal of Immunology, 2014, 44, 1480-1490.	1.6	35
96	Development and Implementation of Papillomavirus Prophylactic Vaccines. Journal of Immunology, 2014, 192, 4007-4011.	0.4	42
97	Indoleamine 2,3-Dioxygenase Activity Contributes to Local Immune Suppression in the Skin Expressing Human Papillomavirus Oncoprotein E7. Journal of Investigative Dermatology, 2013, 133, 2686-2694.	0.3	50
98	Expression of a Single, Viral Oncoprotein in Skin Epithelium Is Sufficient to Recruit Lymphocytes. PLoS ONE, 2013, 8, e57798.	1.1	28
99	A Novel DNA Vaccine Technology Conveying Protection against a Lethal Herpes Simplex Viral Challenge in Mice. PLoS ONE, 2013, 8, e76407.	1.1	47
100	A randomized trial of immunotherapy for persistent genital warts. Human Vaccines and Immunotherapeutics, 2012, 8, 623-629.	1.4	10
101	Response to Comment on "Invariant NKT Cells in Hyperplastic Skin Induced a Local Immune Suppressive Environment by IFN-γ Production― Journal of Immunology, 2012, 188, 931.2-932.	0.4	1
102	Prevalence of Cervical Human Papillomavirus (HPV) Infection in Vanuatu. Cancer Prevention Research, 2012, 5, 746-753.	0.7	13
103	A Combination of Local Inflammation and Central Memory T Cells Potentiates Immunotherapy in the Skin. Journal of Immunology, 2012, 189, 5622-5631.	0.4	14
104	γδT Cells Augment Rejection of Skin Grafts by Enhancing Cross-Priming of CD8 T Cells to Skin-Derived Antigen. Journal of Investigative Dermatology, 2012, 132, 1656-1664.	0.3	19
105	Impact of Sex Steroid Ablation on Viral, Tumour and Vaccine Responses in Aged Mice. PLoS ONE, 2012, 7, e42677.	1.1	24
106	Rapid kinetics to peak serum antibodies is achieved following influenza vaccination by dry-coated densely packed microprojections to skin. Journal of Controlled Release, 2012, 158, 78-84.	4.8	37
107	Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. Journal of Controlled Release, 2012, 159, 215-221.	4.8	81
108	Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer. Current Opinion in Virology, 2011, 1, 268-279.	2.6	15

#	Article	IF	CITATIONS
109	New gene functions in megakaryopoiesis and platelet formation. Nature, 2011, 480, 201-208.	13.7	401
110	Human papillomavirusâ€∱16 E7 protein inhibits interferonâ€Î³â€mediated enhancement of keratinocyte antigen processing and Tâ€cell lysis. FEBS Journal, 2011, 278, 955-963.	2.2	24
111	Increasing mechanical stimulus induces migration of Langerhans cells and impairs the immune response to intracutaneously delivered antigen. Experimental Dermatology, 2011, 20, 534-536.	1.4	14
112	Regulation of immune responses to HPVinfection and during HPVâ€directed immunotherapy. Immunological Reviews, 2011, 239, 85-98.	2.8	60
113	Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. Journal of Controlled Release, 2011, 152, 349-355.	4.8	166
114	Prevention and Treatment of Papillomavirus-Related Cancers Through Immunization. Annual Review of Immunology, 2011, 29, 111-138.	9.5	92
115	<i>LPAR1</i> and <i>ITGA4</i> regulate peripheral blood monocyte counts. Human Mutation, 2011, 32, 873-876.	1.1	20
116	NKT Cells Inhibit Antigen-Specific Effector CD8 T Cell Induction to Skin Viral Proteins. Journal of Immunology, 2011, 187, 1601-1608.	0.4	33
117	New Approaches to Immunotherapy for HPV Associated Cancers. Cancers, 2011, 3, 3461-3495.	1.7	33
118	ILâ€1 signalling determines the fate of skin grafts expressing nonâ€self protein in keratinocytes. Experimental Dermatology, 2010, 19, 723-729.	1.4	8
119	Cervical cancer vaccine development. Sexual Health, 2010, 7, 230.	0.4	11
120	Quantitative Trait Loci for CD4:CD8 Lymphocyte Ratio Are Associated with Risk of Type 1 Diabetes and HIV-1 Immune Control. American Journal of Human Genetics, 2010, 86, 88-92.	2.6	80
121	Expression of papillomavirus L1 proteins regulated by authentic gene codon usage is favoured in G2/M-like cells in differentiating keratinocytes. Virology, 2010, 399, 46-58.	1.1	15
122	The two faces of human papillomavirus. Gynecologic Oncology, 2010, 117, S4.	0.6	2
123	Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecologic Oncology, 2010, 118, S8-S11.	0.6	51
124	Nanopatchâ€Targeted Skin Vaccination against West Nile Virus and Chikungunya Virus in Mice. Small, 2010, 6, 1776-1784.	5.2	150
125	Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model. PLoS ONE, 2010, 5, e10266.	1.1	154
126	Skin Vaccination against Cervical Cancer Associated Human Papillomavirus with a Novel Micro-Projection Array in a Mouse Model. PLoS ONE, 2010, 5, e13460.	1.1	97

#	Article	IF	CITATIONS
127	Secretion of IFN-Î ³ but Not IL-17 by CD1d-Restricted NKT Cells Enhances Rejection of Skin Grafts Expressing Epithelial Cell-Derived Antigen. Journal of Immunology, 2010, 184, 5663-5669.	0.4	30
128	Invariant NKT Cells in Hyperplastic Skin Induce a Local Immune Suppressive Environment by IFN-Î ³ Production. Journal of Immunology, 2010, 184, 1242-1250.	0.4	56
129	Antigen-Specific CD4 Cells Assist CD8 T-Effector Cells in Eliminating Keratinocytes. Journal of Investigative Dermatology, 2010, 130, 1581-1589.	0.3	19
130	Antigen-Specific CD8 T Cells Can Eliminate Antigen-Bearing Keratinocytes with Clonogenic Potential via an IFN-Î ³ -Dependent Mechanism. Journal of Investigative Dermatology, 2010, 130, 1841-1848.	0.3	3
131	Evaluation of a Cervical Cancer Screening Program Based on HPV Testing and LLETZ Excision in a Low Resource Setting. PLoS ONE, 2010, 5, e13266.	1.1	20
132	IFN-Î ³ Promotes Generation of IL-10 Secreting CD4+ T Cells that Suppress Generation of CD8 Responses in an Antigen-Experienced Host. Journal of Immunology, 2009, 183, 51-58.	0.4	40
133	Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. Journal of Controlled Release, 2009, 139, 212-220.	4.8	175
134	Interaction of human papillomaviruses with the host immune system: A well evolved relationship. Virology, 2009, 384, 410-414.	1.1	169
135	Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 Tâ€cell suppression mediated by CD4 ⁺ CD25 ⁺ T cells. European Journal of Immunology, 2009, 39, 481-490.	1.6	37
136	Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nature Genetics, 2009, 41, 1173-1175.	9.4	226
137	Keratinocytes efficiently process endogenous antigens for cytotoxic Tâ€cell mediated lysis. Experimental Dermatology, 2009, 18, 1053-1059.	1.4	6
138	Sequence Variants in Three Loci Influence Monocyte Counts and Erythrocyte Volume. American Journal of Human Genetics, 2009, 85, 745-749.	2.6	73
139	Cortisol changes interact with the effects of a cognitive behavioural psychological preparation for surgery on 12-month outcomes for surgical heart patients. Psychology and Health, 2009, 24, 1139-1152.	1.2	4
140	Development of therapeutic HPV vaccines. Lancet Oncology, The, 2009, 10, 975-980.	5.1	88
141	TLR7 stimulation augments T effectorâ€mediated rejection of skin expressing neoâ€self antigen in keratinocytes. European Journal of Immunology, 2008, 38, 73-81.	1.6	18
142	Up-regulated expression of Sp1 protein coincident with a viral protein in human and mouse differentiating keratinocytes may act as a cell differentiation marker. Differentiation, 2008, 76, 1068-1080.	1.0	10
143	Autoimmunity and persistent viral infection: Two sides of the same coin?. Journal of Autoimmunity, 2008, 31, 216-218.	3.0	15
144	HPV vaccines and the prevention of cervical cancer. Update on Cancer Therapeutics, 2008, 3, 43-48.	0.9	6

#	Article	IF	CITATIONS
145	Generalized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiation. Nucleic Acids Research, 2007, 35, 4820-4832.	6.5	21
146	Correlating immunity with protection for HPV infection. International Journal of Infectious Diseases, 2007, 11, S10-S16.	1.5	41
147	Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis. Arthritis Research and Therapy, 2007, 9, R39.	1.6	13
148	Prevention of cancer through immunization: Prospects and challenges for the 21st century. European Journal of Immunology, 2007, 37, S148-S155.	1.6	41
149	HPV vaccines: the beginning of the end for cervical cancer. Current Opinion in Immunology, 2007, 19, 232-238.	2.4	40
150	HPV vaccination: what do Queensland parents think?. Australian and New Zealand Journal of Public Health, 2007, 31, 288-289.	0.8	10
151	Calcium enhances mouse keratinocyte differentiation in vitro to differentially regulate expression of papillomavirus authentic and codon modified L1 genes. Virology, 2007, 365, 187-197.	1.1	18
152	HPV immunisation: A significant advance in cancer control. Gynecologic Oncology, 2007, 107, S1.	0.6	5
153	Finding a vaccine for human papillomavirus. Lancet, The, 2006, 367, 2058-2059.	6.3	9
154	God's Gift to Women: The Human Papillomavirus Vaccine. Immunity, 2006, 25, 179-184.	6.6	25
155	Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine, 2006, 24, S106-S113.	1.7	199
156	Delivering Papillomavirus Vaccines When and Where They're Most Needed. Hum Vaccin, 2006, 2, 227-229.	2.4	0
157	Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases. Pediatric Infectious Disease Journal, 2006, 25, S65-S81.	1.1	77
158	IL10 and IL12B polymorphisms each influence ILâ€12p70 secretion by dendritic cells in response to LPS. Immunology and Cell Biology, 2006, 84, 227-232.	1.0	32
159	Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia. International Journal of Gynecological Cancer, 2006, 16, 1032-1035.	1.2	9
160	Genomewide scans of red cell indices suggest linkage on chromosome 6q23. Journal of Medical Genetics, 2006, 44, 24-30.	1.5	14
161	Overcoming Original Antigenic Sin to Generate New CD8 T Cell IFN-Î ³ Responses in an Antigen-Experienced Host. Journal of Immunology, 2006, 177, 2873-2879.	0.4	28
162	Activation of dendritic cells by human papillomavirusâ€like particles through TLR4 and NFâ€îºBâ€mediated signalling, moderated by TGFâ€î². Immunology and Cell Biology, 2005, 83, 83-91.	1.0	55

#	Article	IF	CITATIONS
163	Gene Codon Composition Determines Differentiation-Dependent Expression of a Viral Capsid Gene in Keratinocytes In Vitro and InVivo. Molecular and Cellular Biology, 2005, 25, 8643-8655.	1.1	55
164	Is vaccine therapy the future in cancer prevention?. Expert Opinion on Pharmacotherapy, 2004, 5, 2427-2434.	0.9	1
165	tRNASer(CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes. Nucleic Acids Research, 2004, 32, 4448-4461.	6.5	30
166	Impaired Antigen Presentation and Effectiveness of Combined Active/Passive Immunotherapy for Epithelial Tumors. Journal of the National Cancer Institute, 2004, 96, 1611-1619.	3.0	59
167	Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes. Journal of Leukocyte Biology, 2004, 76, 787-795.	1.5	7
168	Human growth hormone presented by K14hGHâ€ŧransgenic skin grafts induces a strong immune response but no graft rejection. Immunology and Cell Biology, 2004, 82, 577-586.	1.0	8
169	Tumour susceptibility to innate and adaptive immunotherapy changes during tumour maturation. Immunology and Cell Biology, 2004, 82, 455-461.	1.0	4
170	Prevention of cervical cancer through papillomavirus vaccination. Nature Reviews Immunology, 2004, 4, 46-55.	10.6	329
171	Multivariate QTL linkage analysis suggests a QTL for platelet count on chromosome 19q. European Journal of Human Genetics, 2004, 12, 835-842.	1.4	17
172	A major quantitative trait locus for CD4–CD8 ratio is located on chromosome 11. Genes and Immunity, 2004, 5, 548-552.	2.2	24
173	Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology, 2004, 324, 297-310.	1.1	63
174	Mutations in TAP genes are common in cervical carcinomas. Gynecologic Oncology, 2004, 92, 914-921.	0.6	34
175	Major quantitative trait locus for eosinophil count is located on chromosome 2q. Journal of Allergy and Clinical Immunology, 2004, 114, 826-830.	1.5	32
176	ISCOMATRIXâ,,¢ adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine, 2004, 22, 3738-3743.	1.7	35
177	Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX? adjuvant in women with cervical intraepithelial neoplasia. Vaccine, 2004, 23, 172-181.	1.7	160
178	Functional memory CD8+ T cells can be generated in vivo without evident T help. Vaccine, 2004, 23, 739-742.	1.7	1
179	B cell chronic lymphocytic leukaemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-γ. Pathology, 2004, 36, 69-76.	0.3	5
180	Effects of additional sequences directly downstream from the AUG on the expression of GFP gene. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2003, 1630, 84-95.	2.4	10

#	Article	IF	CITATIONS
181	Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. Immunology and Cell Biology, 2003, 81, 1-7.	1.0	25
182	Codon usage bias and A+T content variation in human papillomavirus genomes. Virus Research, 2003, 98, 95-104.	1.1	75
183	IL-10 Mediates Suppression of the CD8 T Cell IFN-Î ³ Response to a Novel Viral Epitope in a Primed Host. Journal of Immunology, 2003, 171, 4765-4772.	0.4	48
184	Chapter 16: Prophylactic Human Papillomavirus Vaccines. Journal of the National Cancer Institute Monographs, 2003, 2003, 111-116.	0.9	54
185	Expression of the HPV16E7 Oncoprotein by Thymic Epithelium is Accompanied by Disrupted T Cell Maturation and a Failure of the Thymus to Involute with Age. Clinical and Developmental Immunology, 2003, 10, 91-103.	3.3	10
186	Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Research, 2003, 63, 3058-60.	0.4	42
187	Replication of Bovine Papillomavirus Type 1 (BPV-1) DNA in Saccharomyces cerevisiae following Infection with BPV-1 Virions. Journal of Virology, 2002, 76, 3359-3364.	1.5	31
188	Saccharomyces cerevisiae Is Permissive for Replication of Bovine Papillomavirus Type 1. Journal of Virology, 2002, 76, 12265-12273.	1.5	31
189	Vaccines for papillomavirus infection. Virus Research, 2002, 89, 271-274.	1.1	33
190	The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation. European Journal of Immunology, 2002, 32, 1541.	1.6	41
191	Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunology and Cell Biology, 2002, 80, 21-29.	1.0	30
192	Nuclear RelB+cells are found in normal lymphoid organs and in peripheral tissue in the context of inflammation, but not under normal resting conditions. Immunology and Cell Biology, 2002, 80, 164-169.	1.0	23
193	Interferonâ€gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Immunology and Cell Biology, 2002, 80, 415-424.	1.0	27
194	Codon Modified Human Papillomavirus Type 16 E7 DNA Vaccine Enhances Cytotoxic T-Lymphocyte Induction and Anti-tumour Activity. Virology, 2002, 301, 43-52.	1.1	87
195	Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Research, 2002, 62, 6438-41.	0.4	121
196	Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine, 2001, 20, 862-869.	1.7	68
197	Low level expression of human papillomavirus type 16 (HPV16) E6 in squamous epithelium does not elicit E6 specific B- or T-helper immunological responses, or influence the outcome of immunisation with E6 protein. Virus Research, 2001, 73, 189-199.	1.1	9
198	Developmental Genetics of Red Cell Indices During Puberty: A Longitudinal Twin Study. International Journal of Human Genetics, 2001, 1, 41-53.	0.1	5

#	Article	IF	CITATIONS
199	Efficiency of delivery of DNA to cells by bovine papillomavirus type-1 L1/L2 pseudovirions. Applied Microbiology and Biotechnology, 2001, 56, 150-156.	1.7	4
200	Association of Bovine Papillomavirus Type 1 with Microtubules. Virology, 2001, 282, 237-244.	1.1	28
201	Association of clinical, radiological and synovial immunopathological responses to antiâ€rheumatic treatment in rheumatoid arthritis. Rheumatology, 2001, 40, 1243-1255.	0.9	18
202	Re: Cervical Carcinoma and Human Papillomavirus: On the Road to Preventing a Major Human Cancer. Journal of the National Cancer Institute, 2001, 93, 1349-1350.	3.0	12
203	Nonspecific Down-Regulation of CD8 + T-Cell Responses in Mice Expressing Human Papillomavirus Type 16 E7 Oncoprotein from the Keratin-14 Promoter. Journal of Virology, 2001, 75, 5985-5997.	1.5	19
204	Tolerance or Immunity to a Tumor Antigen Expressed in Somatic Cells Can Be Determined by Systemic Proinflammatory Signals at the Time of First Antigen Exposure. Journal of Immunology, 2001, 167, 6180-6187.	0.4	47
205	E2F-1 induces proliferation-specific genes and suppresses squamous differentiation-specific genes in human epidermal keratinocytes. Oncogene, 2000, 19, 2887-2894.	2.6	35
206	BPV1 E2 Protein Enhances Packaging of Full-Length Plasmid DNA in BPV1 Pseudovirions. Virology, 2000, 272, 382-393.	1.1	27
207	Papillomavirus Virus-like Particles for the Delivery of Multiple Cytotoxic T Cell Epitopes. Virology, 2000, 273, 374-382.	1.1	58
208	Differences in the post-translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system compared with a vaccinia virus system. Biotechnology and Applied Biochemistry, 2000, 32, 27.	1.4	22
209	Multiple Conformational Epitopes Are Recognized by Natural and Induced Immunity to the E7 Protein of Human Papilloma Virus Type 16 in Man. Intervirology, 2000, 43, 165-173.	1.2	3
210	HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine, 2000, 18, 1051-1058.	1.7	145
211	Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine, 2000, 18, 2444-2453.	1.7	61
212	T Cell-Mediated and Non-Specific Inflammatory Mechanisms Contribute to the Skin Pathology of HPV 16 E6E7 Transgenic Mice. Intervirology, 1999, 42, 43-50.	1.2	6
213	Papillomavirus Capsid Protein Expression Level Depends on the Match between Codon Usage and tRNA Availability. Journal of Virology, 1999, 73, 4972-4982.	1.5	223
214	T-Helper Epitopes Identified Within the E6 Transforming Protein of Cervical Cancer-Associated Human Papillomavirus Type 16. Viral Immunology, 1999, 12, 297-312.	0.6	7
215	Genetic and environmental causes of variation in basal levels of blood cells. Twin Research and Human Genetics, 1999, 2, 250-257.	1.5	133
216	Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clinical and Experimental Immunology, 1999, 115, 397-403.	1.1	49

#	Article	IF	CITATIONS
217	Potential strategies utilised by papillomavirus to evade host immunity. Immunological Reviews, 1999, 168, 131-142.	2.8	96
218	Nucleotides 1506–1625 of Bovine Papillomavirus Type 1 Genome Can Enhance DNA Packaging by L1/L2 Capsids. Virology, 1999, 259, 211-218.	1.1	19
219	Expression of the α6 Integrin Confers Papillomavirus Binding upon Receptor-Negative B-Cells. Virology, 1999, 261, 271-279.	1.1	100
220	Construction and production of fluorescent papillomavirus-like particles. Journal of Tongji Medical University, 1999, 19, 170-174.	0.1	4
221	Post translational modifications of recombinant human Papillomavirus type 6b major capsid protein. Virus Research, 1999, 60, 113-121.	1.1	9
222	Capture ELISA and in vitro cell binding assay for the detection of antibodies to human papillomavirus type 6b virus-like particles in patients with anogenital warts. Pathology, 1999, 31, 418-422.	0.3	4
223	Genetic and environmental causes of variation in basal levels of blood cells. Twin Research and Human Genetics, 1999, 2, 250-7.	1.5	115
224	Papillomavirus Virus-like Particles Can Deliver Defined CTL Epitopes to the MHC Class I Pathway. Virology, 1998, 240, 147-157.	1.1	107
225	Type Specific and Genotype Cross Reactive B Epitopes of the L1 Protein of HPV16 Defined by a Panel of Monoclonal Antibodies. Virology, 1998, 243, 275-282.	1.1	18
226	DNA Packaging by L1 and L2 Capsid Proteins of Bovine Papillomavirus Type 1. Virology, 1998, 243, 482-491.	1.1	63
227	Mucosal Immunisation with Papillomavirus Virus-like Particles Elicits Systemic and Mucosal Immunity in Mice. Virology, 1998, 252, 39-45.	1.1	87
228	Split tolerance to a viral antigen expressed in thymic epithelium and keratinocytes. European Journal of Immunology, 1998, 28, 2791-2800.	1.6	40
229	Vaccineâ€Induced Th1â€Type Responses are Dominant over Th2â€Type Responses in the Short Term whereas Preâ€existing Th2 Responses are Dominant in the Longer Term. Scandinavian Journal of Immunology, 1998, 47, 459-465.	1.3	37
230	Histologic and immunohistochemical responses after aortic valve allografts in the rat. Annals of Thoracic Surgery, 1998, 66, S216-S220.	0.7	29
231	SIMPLIFYING THE MOLECULAR MECHANISMS OF HUMAN PAPILLOMAVIRUS. Dermatologic Clinics, 1998, 16, 823-827.	1.0	3
232	Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. Journal of Immunology, 1998, 161, 2421-7.	0.4	44
233	The role of the immune system in anogenital human papillomavirus. Australasian Journal of Dermatology, 1998, 39 Suppl 1, S5-7.	0.4	3
234	Strategies for immunoprophylaxis and immunotherapy of papillomaviruses. Clinics in Dermatology, 1997, 15, 285-297.	0.8	8

#	Article	IF	CITATIONS
235	E7 Oncoprotein of Human Papillomavirus Type 16 Expressed Constitutively in the Epidermis Has No Effect on E7-Specific B- or Th-Repertoires or on the Immune Response Induced or Sustained after Immunization with E7 Protein. Virology, 1997, 231, 155-165.	1.1	26
236	Presentation of the HPV16E7 Protein by Skin Grafts Is Insufficient to Allow Graft Rejection in an E7-Primed Animal. Virology, 1997, 235, 94-103.	1.1	61
237	Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. Journal of Virology, 1997, 71, 2449-2456.	1.5	299
238	Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen. Vaccine, 1996, 14, 545-552.	1.7	65
239	Epithelial Cells Display Separate Receptors for Papillomavirus VLPs and for Soluble L1 Capsid Protein. Virology, 1996, 216, 35-45.	1.1	46
240	Human aortic valve allografts elicit a donor-specific immune response. Journal of Thoracic and Cardiovascular Surgery, 1996, 112, 1260-1267.	0.4	81
241	Immunology of papillomavirus infection. Current Opinion in Immunology, 1996, 8, 484-491.	2.4	88
242	The role of vaccines in the control of STDs: HPV vaccines Sexually Transmitted Infections, 1996, 72, 398-403.	0.8	7
243	Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts Sexually Transmitted Infections, 1996, 72, 103-107.	0.8	9
244	Managing HIV. Part 3: Mechanisms of disease. 3.6 How HIV promotes malignancies. Medical Journal of Australia, 1996, 164, 230-2.	0.8	0
245	Sequences Required for the Nuclear Targeting and Accumulation of Human Papillomavirus Type 6B L2 Protein. Virology, 1995, 213, 321-327.	1.1	29
246	Section Review: Biologicals & Immunologicals: Human papillomavirus infection, genital warts and cervical cancer: prospects for prophylactic and therapeutic vaccines. Expert Opinion on Investigational Drugs, 1995, 4, 783-797.	1.9	6
247	Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgC2a production. Vaccine, 1995, 13, 1460-1467.	1.7	37
248	T-helper epitopes of the E7 transforming protein of cervical cancer associated human papillomavirus type 18 (HPV18). Virus Research, 1995, 36, 1-13.	1.1	15
249	Papillomavirus capsid binding and uptake by cells from different tissues and species. Journal of Virology, 1995, 69, 948-954.	1.5	144
250	Immunological responses in human papillomavirus 16 E6/E7-transgenic mice to E7 protein correlate with the presence of skin disease. Cancer Research, 1995, 55, 2635-9.	0.4	33
251	Routine HIV testing before surgery. Australian Journal of Public Health, 1995, 19, 107-8.	0.2	1
252	Human papillomavirus (HPV) type 18 E7 protein is a short-lived steroid-inducible phosphoprotein in HPV-transformed cell lines. Journal of General Virology, 1994, 75, 1647-1653.	1.3	40

#	Article	IF	CITATIONS
253	Donor-specific immune response after aortic valve allografting in the rat. Annals of Thoracic Surgery, 1994, 57, 1158-1163.	0.7	47
254	Immune Response to Human Papillomaviruses and the Prospects for Human Papillomavirus-Specific Immunisation. Current Topics in Microbiology and Immunology, 1994, 186, 217-253.	0.7	50
255	Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence. Journal of Virology, 1994, 68, 619-625.	1.5	95
256	Glycosylation of Human Papillomavirus Type 16 L1 Protein. Virology, 1993, 194, 210-218.	1.1	21
257	Human papillomavirus type 16 E6, E7 and L1 and type 18 E7 proteins produced by recombinant baculoviruses. Journal of Virological Methods, 1993, 45, 303-318.	1.0	36
258	Synthesis and assembly of infectious bovine papillomavirus particles in vitro. Journal of General Virology, 1993, 74, 763-768.	1.3	128
259	Transmission of Human Papillomaviruses from Mother to Child. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1993, 33, 30-32.	0.4	86
260	HPV DNA in oropharyngeal squamous cell cancers: comparison of results from four DNA detection methods. Pathology, 1993, 25, 138-143.	0.3	13
261	An ELISA capture assay for the E7 transforming proteins of HPV16 and HPV18. Journal of Virological Methods, 1992, 37, 119-127.	1.0	12
262	Human papillomaviruses in normal oral mucosa: a comparison of methods for sample collection. Journal of Oral Pathology and Medicine, 1992, 21, 265-269.	1.4	111
263	Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology, 1992, 189, 592-599.	1.1	45
264	The hygromycin-resistance-eneoding gene as a selection marker for vaccinia virus recombinants. Gene, 1991, 107, 307-312.	1.0	15
265	Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology, 1991, 185, 251-257.	1.1	488
266	A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5887-5891	3.3	156
267	Immunology of Anogenital Human Papillomavirus (HPV) Infection. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1990, 30, 370-375.	0.4	10
268	Major population differences in T cell response to a malaria sporozite vaccine candidate. International Immunology, 1990, 2, 945-955.	1.8	53
269	Immunology of Papillomavirus Infection of the Human Anogenital Epithelium. Journal of Gynecologic Surgery, 1990, 6, 11-21.	0.0	0
270	Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein. Journal of General Virology, 1990, 71, 1347-1354.	1.3	63

#	Article	IF	CITATIONS
271	A neonatally tolerant mouse model to assess pathogenicity of human autoantibodies. Journal of Immunological Methods, 1990, 127, 279-284.	0.6	4
272	Identification of B-epitopes in the human papillomavirus 18 E7 open reading frame protein. Journal of Immunology, 1990, 145, 3105-10.	0.4	17
273	The molecular specificity of linear B-epitopes in the E7 open reading frame protein of human papillomavirus 16 defined by monoclonal antibodies. Peptide Research, 1990, 3, 162-6.	0.2	2
274	CEREBRAL DYSFUNCTION WITH EVIDENCE OF CEREBRAL HIV INFECTION AMONGST ASYMPTOMATIC HIV SEROPOSITIVE SUBJECTS. Australian and New Zealand Journal of Medicine, 1989, 19, 694-699.	0.5	11
275	Male partners of women with genital human papillomavirus infection: An assessment of colposcopic abnormalities by histological examination and human papillomavirus hybridization. Medical Journal of Australia, 1989, 150, 479-482.	0.8	9
276	Depressed activities of purine enzymes in lymphocytes of patients infected with human immunodeficiency virus. Clinical Chemistry, 1989, 35, 1478-81.	1.5	1
277	A biometrical view on normal values of CD4 and CD8 lymphocyte counts in peripheral blood. Pathology, 1988, 20, 358-360.	0.3	5
278	Human papillomavirus — a study of male sexual partners. Medical Journal of Australia, 1988, 149, 309-311.	0.8	26
279	Influence of human immunodeficiency virus antibody testing on sexual behaviour in a "highâ€risk― population from a "lowâ€risk―city. Medical Journal of Australia, 1988, 149, 365-368.	0.8	14
280	Antibody to liver membrane antigens in chronic active hepatitis. IV. Exclusion of specific reactivity to polypeptides and glycolipids by immunoblotting. Hepatology, 1987, 7, 4-10.	3.6	28
281	Intramuscular versus low-dose intradermal hepatitis B vaccine. Assessment by humoral and cellular immune response to hepatitis B surface antigen. Medical Journal of Australia, 1987, 146, 242-5.	0.8	7
282	Immunoregulatory defects associated with infection with the AIDS virus, HTLV-III. Concepts in Immunopathology, 1987, 4, 243-60.	0.3	3
283	Auto-Epitopes and Autoimmune Diseases. Annals of the New York Academy of Sciences, 1986, 475, 59-65.	1.8	5
284	ASSOCIATION BETWEEN ANORECTAL DYSPLASIA, HUMAN PAPILLOMAVIRUS, AND HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HOMOSEXUAL MEN. Lancet, The, 1986, 328, 657-660.	6.3	186
285	Second International Conference on the acquired immune deficiency syndrome. Medical Journal of Australia, 1986, 145, 524-529.	0.8	2
286	[71] A rapid micromethod for the enumeration of T cell subsets in blood by epifluorescence microscopy. Methods in Enzymology, 1986, 121, 748-758.	0.4	0
287	â€~Acute' Autoimmune Hepatitis. Digestion, 1986, 34, 216-225.	1.2	66
288	Cell-mediated immunity to hepatitis B virus antigens in mice: correlation of in vivo and in vitro assays. Clinical and Experimental Immunology, 1986, 64, 285-94.	1.1	6

#	Article	IF	CITATIONS
289	A graphical presentation of counts of T lymphocyte subpopulations and Th-Ts ratios. Pathology, 1985, 17, 62-63.	0.3	2
290	Antibody to G-actin in different categories of alcoholic liver disease: Quantification by an ELISA and significance for alcoholic cirrhosis. Clinical Immunology and Immunopathology, 1985, 34, 158-164.	2.1	19
291	Assessment of delayed-type hypersensitivity in man: A comparison of the "Multitest―and conventional intradermal injection of six antigens. Clinical Immunology and Immunopathology, 1985, 35, 182-190.	2.1	48
292	IDIOPATHIC NEUTROPENIA IN HOMOSEXUAL MEN. Lancet, The, 1985, 325, 936-937.	6.3	10
293	The cellular infiltrate in the liver in autoâ€immune chronic active hepatitis: analysis with monoclonal antibodies. Liver, 1985, 5, 162-172.	0.1	25
294	First International Conference on the Acquired Immunodeficiency Syndrome. Medical Journal of Australia, 1985, 143, 31-34.	0.8	3
295	Absence of autoimmune serological reactions in chronic non A, non B viral hepatitis. Clinical and Experimental Immunology, 1985, 61, 39-43.	1.1	32
296	Reactivity of anti-mitochondrial autoantibodies in primary biliary cirrhosis: definition of two novel mitochondrial polypeptide autoantigens. Journal of Immunology, 1985, 135, 1739-45.	0.4	109
297	The 1984 International Symposium on Viral Hepatitis. Medical Journal of Australia, 1984, 140, 712-714.	0.8	1
298	Antibody to human T cell leukaemia virus type III in Australian homosexual men with lymphadenopathy. Medical Journal of Australia, 1984, 141, 274-276.	0.8	10
299	Antibodies to liver cell membrane antigens in chronic active hepatitis (CAH). III. Partial characterization of the liver cell membrane antigens and comparison of reactivities in sera from patients with various liver diseases. Clinical and Experimental Immunology, 1984, 57, 429-37.	1.1	8
300	Immune responses to liver-specific lipoprotein and liver membrane antigen: a tabular interpretative review. Journal of Clinical & Laboratory Immunology, 1984, 14, 165-7.	0.1	3
301	Autoantibodies, sheep cell agglutinins and anti-albumin antibodies in alcoholic liver disease. Journal of Clinical & Laboratory Immunology, 1984, 13, 21-4.	0.1	5
302	A rapid micromethod for evaluating T cell subsets in blood using monoclonal antisera. Journal of Immunological Methods, 1983, 57, 137-145.	0.6	2
303	Pleuroperitoneal effusion without ascites. Medical Journal of Australia, 1983, 2, 520-521.	0.8	22
304	Antibodies to liver membrane antigens in chronic active hepatitis (CAH). II. Specificity for autoimmune CAH. Clinical and Experimental Immunology, 1983, 54, 213-8.	1.1	32
305	Fundamental and applied aspects of rheumatoid arthritis. Medical Journal of Australia, 1983, 1, 516-518.	0.8	0
306	Spontaneous reverse hemolytic plaque formation. Clinical Immunology and Immunopathology, 1982, 24, 386-395.	2.1	13

#	Article	IF	CITATIONS
307	T lymphocyte subpopulations defined by two sets of monoclonal antibodies in chronic active hepatitis and systemic lupus erythematosus. Clinical and Experimental Immunology, 1982, 50, 107-14.	1.1	20
308	Autoantibodies to liver antigens in chronic liver disease. I. A radioimmunoassay for antibody to liver membrane antigens. Journal of Clinical & Laboratory Immunology, 1982, 9, 207-11.	0.1	5
309	Is infusion phlebitis preventable?. BMJ: British Medical Journal, 1977, 2, 232-232.	2.4	7
310	Vaccines to Prevent and Treat Human Papillomavirus-Associated Anogenital Disease. , 0, , 609-621.		2